Quick Facts: Therapeutic Domains

• May be considered for the management of severe acne and excessive hair growth (hirsutism) in women.
• Used in the therapeutic regimen for advanced prostate carcinoma (cancer).

Cyproterone Acetate is a medication used to address conditions influenced by male hormones (androgens). Its primary therapeutic application is in the management of prostate carcinoma. For this specific use, it forms part of a hormonal treatment strategy for inoperable or advanced stages of the disease, often to mitigate the temporary rise in hormone levels that can occur when starting certain other therapies.

In women of reproductive age, Cyproterone Acetate, typically in combination with an estrogen, may be considered for the management of androgen-related conditions. These conditions include severe acne and hirsutism (excessive, unwanted hair growth). For these dermatological concerns, this treatment is generally reserved for patients when other systemic or topical treatment options have not provided adequate results.

Its approved indications and recommended clinical use are subject to specific regulatory guidelines and patient criteria.

---

Regulatory References

1. EMA therapeutic overview

Eligibility and Contraindications

Cyproterone Acetate's use is strictly defined by regulatory eligibility criteria. The medicine is contraindicated in patients with a current or past history of meningioma, which is an absolute prohibition regardless of the dose. Absolute non-eligibility also applies to individuals with a history of venous or arterial thromboembolism (blood clots), or those with severe liver disease or the presence of liver tumors.

Use is formally contraindicated during both pregnancy and lactation. In the pediatric population, the medicine is not recommended in children and adolescents under 18 years and is strictly prohibited before the conclusion of puberty.

Restricted and Allowed Populations

Cyproterone Acetate is approved for adult men (prostate carcinoma) and women of reproductive age (androgen-related conditions). However, use in women is often restricted to cases where alternative systemic treatments have failed. Patients with certain comorbidities, such as diabetes mellitus, require careful monitoring to ensure continued eligibility.

Cyproterone acetate is primarily metabolized by the Cytochrome P450 enzyme CYP3A4 in the liver. Due to this pathway, other medicines that affect the activity of CYP3A4 can alter the concentration of cyproterone acetate in the blood, potentially changing its therapeutic effect or increasing the risk of side effects.

Medicines that Increase Cyproterone Acetate Levels

CYP3A4 inhibitors slow down the breakdown of cyproterone acetate, which can increase its concentration in the body and heighten the risk of side effects, particularly liver toxicity. Examples of these inhibitors include certain antifungal medications (e.g., ketoconazole, itraconazole), antivirals (e.g., ritonavir), and macrolide antibiotics (e.g., erythromycin, clarithromycin). If combined, dosage adjustments may be necessary.

Medicines and Products that Decrease Cyproterone Acetate Levels

CYP3A4 inducers speed up the breakdown of cyproterone acetate, which can lead to lower therapeutic levels and reduced effectiveness. Examples of inducers include certain anti-epileptic drugs (e.g., phenytoin, phenobarbital), the antibiotic rifampicin, and the herbal supplement St. John's wort.

Other Important Interactions

• Oral Hypoglycemics/Insulin: Cyproterone acetate may affect glucose metabolism, possibly decreasing the effectiveness of medications used to manage diabetes. Patients with diabetes require close monitoring.
• Alcohol: Alcohol intake may reduce the antiandrogenic effect of cyproterone acetate, and patients are generally advised to limit its use.

Cyproterone Acetate (CPA) functions primarily through two distinct pharmacodynamic mechanisms: androgen receptor (AR) antagonism and gonadotropin suppression via progestogenic activity.

CPA acts as a high-affinity competitive antagonist at the intracellular androgen receptor, particularly in androgen-sensitive tissues such as the prostate, sebaceous glands, and hair follicles. By binding to the AR with greater affinity than the endogenous ligand dihydrotestosterone (DHT), CPA prevents the translocation of the receptor complex into the nucleus. This molecular interaction physically blocks the activation of androgen response elements (AREs) on target DNA, thereby inhibiting the transcription of androgen-dependent genes and subsequent protein synthesis.

Concurrently, CPA exhibits agonist activity at the intracellular progesterone receptor (PR). This progestational effect modulates the hypothalamic-pituitary-gonadal (HPG) axis. Specifically, the activation of PRs in the pituitary gland exerts negative feedback on the hypothalamus, resulting in a dose-dependent reduction in the pulsatile release of gonadotropin-releasing hormone (GnRH). The downstream cascade involves a diminished secretion of pituitary luteinizing hormone (LH), which, in turn, decreases Leydig cell stimulation. The system-level physiological consequence of this central action is a substantial reduction in testosterone biosynthesis and circulating androgen levels.

Cyproterone Acetate is formally administered via the oral route as a tablet preparation, and an intramuscular injection is also used for high-dose administration. The prescribed administration schedule is determined by the specific treatment protocol.

For high-dose regimens, the oral dose typically ranges from 100 mg to 300 mg daily. This total daily amount is conventionally divided into two or three separate administrations taken throughout the day and is usually followed as a continuous, long-term protocol. In contrast, the low-dose preparation, which contains 2 mg of CPA, is used according to a cyclical schedule. This pattern involves once-daily intake for 21 consecutive days, immediately followed by a 7-day period where no tablet is taken, thus establishing a defined treatment cycle.

A key instruction for oral administration is that tablets must be taken after meals with some liquid to standardize the intake condition. Furthermore, there are specific administrative considerations for certain populations: the medicine is not recommended for use in male patients under 18 years. Procedurally, any required reduction in the high-dose daily amount must be implemented gradually and not abruptly. The continuation of treatment follows the structure established by the regimen, whether cyclic or continuous.

Research Evidence / Overview of Studies for Cyproterone Acetate

Evidence for Use in Advanced Prostate Carcinoma

Research into Cyproterone Acetate for advanced prostate carcinoma (cancer) has been conducted primarily through large-scale Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses. These studies focused on understanding the long-term patterns observed in adult men diagnosed with advanced disease. Researchers monitored outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS), which are measures used in research to evaluate outcomes related to survival duration or disease progression in the study populations.

Findings from these studies suggest patterns related to survival when Cyproterone Acetate was used as part of combination treatments. Some findings described observed survival patterns when compared to other standard regimens studied. The research primarily examined the role of this medicine within comparative treatment strategies.

Evidence for Use in Androgen-Related Conditions in Women

Research for Cyproterone Acetate in women of reproductive age was studied for conditions characterized by fluctuating or episodic manifestations like severe acne and hirsutism (excessive hair growth). Studies have been conducted using Randomized Controlled Trials, where the medicine is typically administered in a combination product. Researchers examined changes in symptoms using clinical assessments like the Ferriman-Gallwey (FG) Score for hirsutism. Trials report how symptoms evolved in the observed populations over defined time intervals, and studies were observed that included data for certain groups, such as those with Polycystic Ovary Syndrome (PCOS), as part of subgroups.

Long-Term Study Findings and Follow-Up Duration

For prostate carcinoma, trials often involved medium to long-term follow-up, with observation periods extending to two to five years or more. For androgen-related conditions in women, the studies were generally short-term, typically ranging from six to twelve months. Follow-up durations were limited in many dermatological trials, which means that long-term effects are not fully established regarding the sustained response after treatment is stopped or after several years of use.

Evidence Gaps and Research Uncertainty

A review of the available research highlights several areas where certainty remains low or where data are still emerging. In the context of prostate carcinoma, findings were mixed regarding outcomes related to overall survival when using combination therapy. For androgen-related conditions, the primary research limitations include small sample sizes and a lack of standardized objective assessment across all trials. Furthermore, the comparative evidence is lacking for a definitive assessment of this combination against all other available therapies. Research provides context but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Vitamin B12 - MedlinePlus

Common questions about Cyproterone Acetate (FAQ)

Q: Is Cyproterone Acetate a type of hormone or is it a hormone blocker?

Official documents describe Cyproterone Acetate as a synthetic steroidal compound that has a dual function. It exhibits hormonal activity by acting as a progestogen, which is a type of hormone. Simultaneously, it acts as a hormone blocker (an anti-androgen) by competitively blocking androgen receptors in the body.

Q: Can Cyproterone Acetate stop my body from producing hormones?

Regulatory information indicates that the medicine has an anti-gonadotropic effect. This action leads to a dose-dependent reduction in the secretion of the luteinizing hormone (LH). This biological change is associated with a resulting decline in the body's natural production of testosterone.

Q: Can Cyproterone Acetate be used long-term?

Cyproterone Acetate is used in continuous, long-term protocols for some indications, such as advanced prostate carcinoma. However, official safety documents warn that risks, like the rare development of meningioma (a brain tumor), increase with long-term use and greater cumulative doses. Official guidance notes that due to this risk, clinical monitoring is required for patients on long-term treatment.

Q: How long does it typically take for the effects of Cyproterone Acetate to become noticeable?

The time required to see the main therapeutic effects can vary by individual and condition. However, pharmacokinetic data shows that stable blood levels (steady-state plasma levels) are typically reached after 6 to 12 days of daily dosing. Official information also notes that associated feelings like tiredness often lessen after about three months of treatment.

Q: If someone stops taking Cyproterone Acetate, how long do its effects stay in the system?

Official documents note that Cyproterone Acetate has a long terminal half-life, meaning it takes a long time for the body to completely clear the medication. In men, certain effects, such as the inhibition of spermatogenesis (sperm production), are documented as being reversible upon discontinuation.

Q: Is it necessary to take Cyproterone Acetate at the exact same time every day?

Yes. Regulatory instructions specify that the tablets should be taken every day at about the same time. Taking the medicine at consistent times is intended to maintain uniform levels of the drug in the body.

Q: What is the recommended procedure if a dose of Cyproterone Acetate is forgotten?

If a dose of the monotherapy tablet is forgotten, official patient information describes the procedure as taking the forgotten dose as soon as possible within the same day. If a full day has passed, the procedure is not to take a double dose, and to resume the standard schedule on the next day.

Q: How is Cyproterone Acetate usually supplied (e.g., tablet size)?

The monotherapy oral formulation is supplied in several different tablet strengths, typically including 10 mg, 50 mg, and 100 mg tablets, as defined in regulatory documents. A high-dose injection formulation (300 mg/3ml) is also documented for certain treatments.

Q: Does taking Cyproterone Acetate affect blood test results for hormones?

Official safety information indicates that Cyproterone Acetate may affect certain laboratory test results, particularly those related to hormone levels, due to its anti-hormonal action. Official documentation notes that patients should inform their healthcare providers and lab workers that they are taking this drug.

Q: Are the side effects associated with Cyproterone Acetate usually temporary or can they be permanent?

The duration of side effects can vary. While some effects, such as the loss of spermatogenesis, are documented as reversible upon stopping the drug, other serious risks may have long-term consequences. For example, the rare development of meningioma requires the permanent discontinuation of the medicine.

Q: What is the risk of blood clots associated with this medication?

The use of Cyproterone Acetate-containing products is associated with an increased risk of venous thromboembolism (blood clots) compared with no use. Regulatory data for combination products categorizes this event as Rare. Official documents specify that this risk is generally highest during the first year of use.

Q: Can Cyproterone Acetate cause mood changes or depression?

Yes, regulatory documents list depressive moods and mood swings as common side effects associated with the medicine. Furthermore, a history of severe chronic depression is also listed as a formal contraindication for using the medicine.

Q: Does Cyproterone Acetate affect fertility in people who take it?

Cyproterone Acetate can affect fertility. In men, it may cause impaired spermatogenesis leading to reversible infertility while the drug is being taken. For women using the low-dose combination product, the cyclical schedule is designed to prevent ovulation and conception.

Q: Are there any warning signs for serious side effects I should know about?

Yes, patients should be aware of warning signs for rare but serious side effects like meningioma, which can include changes in vision, worsening headaches, hearing loss, or memory loss. Official documentation describes the signs of blood clots or liver problems as requiring urgent medical evaluation.

Q: Can Cyproterone Acetate be used safely by people with a history of heart problems?

Regulatory documents state that the medicine is contraindicated (prohibited) in patients with a history of venous or arterial thrombosis (blood clots). This includes certain conditions related to heart health, such as a prior myocardial infarction (heart attack) or angina pectoris.

Q: Is Cyproterone Acetate prescribed to children or adolescents?

Official guidelines state the medicine is not recommended for use in children and adolescents under 18 years of age. It must also not be given before the conclusion of puberty due to the potential influence on growth and endocrine function.

Q: Is Cyproterone Acetate available in different countries under other brand names?

Yes, Cyproterone Acetate is often marketed internationally under various brand names. For example, it is known as Androcur for monotherapy and sometimes as Diane-35 (or co-cyprindiol) for the low-dose combination product.

Q: What are the official guidelines regarding the maximum duration of treatment with Cyproterone Acetate?

While some protocols are continuous and long-term, official guidelines include a caution to use Cyproterone Acetate at the minimum effective dose and for the shortest duration necessary. This is noted especially for non-oncological indications because the risk of meningioma increases with cumulative dose and prolonged exposure.

Q: Has Cyproterone Acetate ever been subject to a major safety warning or product recall?

Yes. Regulatory authorities like the European Medicines Agency (EMA) have issued major safety warnings and usage restrictions in recent years. This was due to the identified risk of meningioma, which increases with cumulative dose.

Q: Are there generic versions of Cyproterone Acetate available?

Yes, official documents show that Cyproterone Acetate is available in generic formulations in addition to branded products. Generic versions are often labeled using the drug's non-proprietary name, such as "Cyproterone Acetate Tablets."

Q: What happens to the body when the anti-androgenic effect of Cyproterone Acetate begins?

The anti-androgenic effects begin by blocking androgen receptors in certain target tissues, such as the sebaceous glands and hair follicles. This mechanism is the basis for its therapeutic use in conditions like severe acne and hirsutism. In male patients, its effects can also lead to signs of demasculinization.

Q: Are there non-hormonal uses for Cyproterone Acetate mentioned in official documents?

No. Regulatory documents classify Cyproterone Acetate as a synthetic steroidal hormonal agent with dual hormonal/anti-hormonal activity. All of its approved therapeutic uses are based entirely on these properties.

Q: How does the mechanism of action differ between high and low doses of Cyproterone Acetate?

The key mechanism for all doses is the anti-androgen effect (blocking androgen receptors). However, the second mechanism, which is gonadotropin suppression (reducing the body's own hormone production), is generally dose-dependent. This means the suppressive effect is more pronounced at higher doses.

Q: Is it true that Cyproterone Acetate can sometimes be used to treat hot flashes?

Yes. Regulatory-supported information and documented clinical research show that Cyproterone Acetate is used to treat hot flashes (or hot flushes). This use is primarily in men who have undergone surgical or chemical castration for prostate cancer.

Q: Does Cyproterone Acetate make people tired or cause insomnia?

Regulatory documents list feelings of fatigue and lassitude (a state of physical or mental weariness) as common adverse reactions. Regulatory documents state that patients may need to use caution when driving or operating machinery if they experience these symptoms.

How to Store and Dispose of Cyproterone Acetate

Official regulatory guidelines define specific conditions to maintain the stability and safety of Cyproterone Acetate tablets. The medicine must be stored at a temperature below 30°C and protected from both light and moisture.

To ensure security and integrity, the tablets must be kept in their original, tightly sealed container and stored locked up, away from the sight and reach of children (P405). The documented shelf-life for the product can range from three to five years, provided it is stored correctly and avoids excess heat.

Disposal must adhere to strict environmental rules. Unused or expired medication must be handled as hazardous waste and disposed of at an approved waste disposal plant in accordance with local regulations. It is strictly prohibited to flush the tablets down toilets or dispose of them in any wastewater system.